Keywords: Biotie, Synosia, M&A, UCB
Biotie to acquire Synosia to create leading CNS development group in $121.5 million deal
Article | 11 January 2011
Finland-based biotech firm Biotie Therapies (Nasdaq-OMX; BTH1V) has signed an accord to acquire privately-held Swiss company Synosia Therapeutics Holding ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
